Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BVS Bioventus	$7.38 -2.1%	$6.71	$5.81 ▼ $14.38	$605.81M	0.83	396,085 shs	262,495 shs
EYE National Vision	$23.11 -0.5%	$23.64	$9.56 ▼ $25.67	$1.83B	1.27	2.10 million shs	627,426 shs
LMAT LeMaitre Vascular	$95.17 +0.0%	$84.08	$71.42 ▼ $109.58	$2.16B	0.79	188,936 shs	100,343 shs
PRCT PROCEPT BioRobotics	$39.96 -1.0%	$55.73	$37.12 ▼ $103.81	$2.22B	1.05	1.02 million shs	748,242 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BVS Bioventus	+3.01%	+3.29%	+10.57%	+15.14%	-4.68%
EYE National Vision	+0.87%	-2.76%	-7.16%	+24.84%	+118.85%
LMAT LeMaitre Vascular	+0.82%	+2.06%	+13.15%	+14.23%	+14.90%
PRCT PROCEPT BioRobotics	+4.61%	-11.62%	-30.58%	-30.51%	-37.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BVS Bioventus	2.973 of 5 stars	3.4	0.0	0.0	0.0	1.8	3.3	1.3
EYE National Vision	2.8394 of 5 stars	2.3	2.0	0.0	3.3	3.9	0.0	0.0
LMAT LeMaitre Vascular	2.2182 of 5 stars	1.3	3.0	3.3	0.0	2.1	2.5	1.3
PRCT PROCEPT BioRobotics	3.073 of 5 stars	4.4	1.0	0.0	0.0	2.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BVS Bioventus	2.75	Moderate Buy	$13.75	86.44% Upside
EYE National Vision	2.60	Moderate Buy	$24.73	7.00% Upside
LMAT LeMaitre Vascular	2.50	Moderate Buy	$98.00	2.97% Upside
PRCT PROCEPT BioRobotics	2.78	Moderate Buy	$74.88	87.38% Upside

Current Analyst Ratings Breakdown

Latest BVS, PRCT, LMAT, and EYE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	EYE National Vision	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$17.00 ➝ $22.00
8/7/2025	EYE National Vision	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$24.00 ➝ $27.00
8/7/2025	EYE National Vision	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$30.00 ➝ $28.00
8/7/2025	PRCT PROCEPT BioRobotics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $58.00
8/7/2025	PRCT PROCEPT BioRobotics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$80.00 ➝ $55.00
8/6/2025	LMAT LeMaitre Vascular	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$92.00 ➝ $95.00
8/6/2025	LMAT LeMaitre Vascular	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$95.00
7/30/2025	EYE National Vision	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$36.00
7/23/2025	EYE National Vision	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $24.00
7/22/2025	LMAT LeMaitre Vascular	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
7/15/2025	PRCT PROCEPT BioRobotics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$71.00 ➝ $68.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BVS Bioventus	$564.14M	1.07	$0.59 per share	12.58	$2.80 per share	2.63
EYE National Vision	$1.82B	1.00	$1.64 per share	14.07	$10.74 per share	2.15
LMAT LeMaitre Vascular	$234.64M	9.18	$2.41 per share	39.51	$16.02 per share	5.94
PRCT PROCEPT BioRobotics	$274.95M	8.09	N/A	N/A	$6.93 per share	5.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BVS Bioventus	-$156.23M	N/A	N/A	16.03	N/A	-7.11%	15.61%	4.01%	N/A
EYE National Vision	-$28.50M	-$0.18	N/A	85.59	2.77	-0.75%	3.56%	1.49%	N/A
LMAT LeMaitre Vascular	$44.04M	$2.06	46.41	43.86	2.43	20.08%	13.67%	9.14%	10/30/2025 (Estimated)
PRCT PROCEPT BioRobotics	-$91.41M	-$1.55	N/A	N/A	N/A	-30.60%	-23.73%	-17.34%	10/27/2025 (Estimated)

Latest BVS, PRCT, LMAT, and EYE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	EYE National Vision	$0.12	$0.18	+$0.06	$0.11	$469.21 million	$486.42 million
8/6/2025	Q2 2025	PRCT PROCEPT BioRobotics	-$0.41	-$0.35	+$0.06	-$0.35	$75.67 million	$79.18 million
8/5/2025	Q2 2025	LMAT LeMaitre Vascular	$0.57	$0.60	+$0.03	$0.60	$62.48 million	$63.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BVS Bioventus	N/A	N/A	N/A	N/A	N/A
EYE National Vision	N/A	N/A	N/A	N/A	N/A
LMAT LeMaitre Vascular	$0.80	0.84%	N/A	38.83%	14 Years
PRCT PROCEPT BioRobotics	N/A	N/A	N/A	N/A	N/A

Latest BVS, PRCT, LMAT, and EYE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2025	LMAT LeMaitre Vascular	quarterly	$0.20	0.9%	8/21/2025	8/21/2025	9/4/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BVS Bioventus	1.85	1.41	0.99
EYE National Vision	0.30	0.52	0.31
LMAT LeMaitre Vascular	0.46	13.96	11.74
PRCT PROCEPT BioRobotics	0.13	9.21	7.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BVS Bioventus	62.94%
EYE National Vision	N/A
LMAT LeMaitre Vascular	84.64%
PRCT PROCEPT BioRobotics	89.46%

Insider Ownership

Company	Insider Ownership
BVS Bioventus	33.00%
EYE National Vision	2.70%
LMAT LeMaitre Vascular	9.50%
PRCT PROCEPT BioRobotics	6.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BVS Bioventus	1,200	82.14 million	54.46 million	Not Optionable
EYE National Vision	13,411	79.20 million	77.06 million	Optionable
LMAT LeMaitre Vascular	490	22.64 million	20.49 million	Optionable
PRCT PROCEPT BioRobotics	430	55.64 million	51.96 million	Optionable

BVS, PRCT, LMAT, and EYE Headlines

Recent News About These Companies

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Shares Bought by Mitsubishi UFJ Asset Management Co. Ltd.

August 14 at 4:15 AM | marketbeat.com

Leerink Partners Reiterates a Buy Rating on PROCEPT BioRobotics (PRCT)

August 13 at 1:59 PM | msn.com

Leerink Partnrs Issues Pessimistic Outlook for PRCT Earnings

August 12 at 2:45 AM | americanbankingnews.com

William Blair Issues Pessimistic Outlook for PRCT Earnings

August 12 at 2:45 AM | americanbankingnews.com

PROCEPT BioRobotics (NASDAQ:PRCT) Stock Rating Upgraded by Wall Street Zen

August 11 at 2:31 AM | americanbankingnews.com

Leerink Partnrs Has Negative Forecast for PRCT Q3 Earnings

August 11 at 2:43 AM | marketbeat.com

William Blair Issues Negative Forecast for PRCT Earnings

August 11 at 2:43 AM | marketbeat.com

PROCEPT BioRobotics (NASDAQ:PRCT) Upgraded to "Hold" at Wall Street Zen

August 10, 2025 | marketbeat.com

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q2 2025 Earnings Call Transcript

August 8, 2025 | msn.com

PROCEPT BioRobotics (NASDAQ:PRCT) Price Target Lowered to $58.00 at Wells Fargo & Company

August 8, 2025 | marketbeat.com

PROCEPT BioRobotics (NASDAQ:PRCT) Shares Gap Down on Analyst Downgrade

August 8, 2025 | marketbeat.com

PROCEPT BioRobotics (NASDAQ:PRCT) Price Target Cut to $55.00 by Analysts at Piper Sandler

August 8, 2025 | marketbeat.com

PROCEPT BioRobotics (NASDAQ:PRCT) Sets New 12-Month Low - Should You Sell?

August 7, 2025 | marketbeat.com

PROCEPT BioRobotics Corporation (PRCT) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Procept (PRCT) Q2 Revenue Jumps 48%

August 7, 2025 | aol.comA

PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2025 | zacks.com

PROCEPT BioRobotics (PRCT) Earnings Transcript

August 6, 2025 | fool.com

PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

August 6, 2025 | globenewswire.com

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Stock Holdings Lifted by Westfield Capital Management Co. LP

August 6, 2025 | marketbeat.com

PROCEPT BioRobotics (NASDAQ:PRCT) Stock Price Down 3.5% - What's Next?

August 5, 2025 | marketbeat.com

Uncovering Potential: PROCEPT BioRobotics's Earnings Preview

August 5, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVS, PRCT, LMAT, and EYE Company Descriptions

Bioventus NYSE:BVS

$7.38 -0.15 (-1.99%)

As of 03:20 PM Eastern

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

National Vision NASDAQ:EYE

$23.11 -0.11 (-0.47%)

As of 03:20 PM Eastern

National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.

LeMaitre Vascular NASDAQ:LMAT

$95.17 +0.02 (+0.02%)

As of 03:19 PM Eastern

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

PROCEPT BioRobotics NASDAQ:PRCT

$39.98 -0.40 (-0.99%)

As of 03:20 PM Eastern

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time